PB2328: TRIAL IN PROGRESS: ATHENA-1 – A PHASE 1 STUDY TO ASSESS SAFETY AND TOLERABILITY OF REGN5837 IN COMBINATION WITH ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA
Pim G. N. J. Mutsaers,
Jeremy S. Abramson,
Manjusha Namuduri,
Jingjin LI,
Nickolas A. Sophos,
Min Zhu,
Jurriaan Brouwer-Visser,
Hesham Mohamed,
Aafia Chaudhry,
Andrew J. Davies
Affiliations
Pim G. N. J. Mutsaers
1 Erasmus University Medical Center, Rotterdam, The Netherlands
Jeremy S. Abramson
2 Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States
Manjusha Namuduri
3 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
Jingjin LI
3 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
Nickolas A. Sophos
3 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
Min Zhu
3 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
Jurriaan Brouwer-Visser
3 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
Hesham Mohamed
3 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
Aafia Chaudhry
3 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
Andrew J. Davies
4 Southampton NIHR/Cancer Research UK Experimental Cancer Medicines Centre, University of Southampton, Southampton, United Kingdom
